{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:44:30Z","timestamp":1790912670348,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T00:00:00Z","timestamp":1416960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00125-014-3458-7","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T08:08:20Z","timestamp":1417421300000},"page":"464-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study"],"prefix":"10.1007","volume":"58","author":[{"given":"Kwok-Leung","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej S.","family":"Januszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia J.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell S.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Riitta","family":"Taskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry-Anne","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,26]]},"reference":[{"key":"3458_CR1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627\u20131635","journal-title":"J Clin Invest"},{"key":"3458_CR2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","volume":"5","author":"MK Badman","year":"2007","unstructured":"Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426\u2013437","journal-title":"Cell Metab"},{"key":"3458_CR3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki T, Dutchak P, Zhao G et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415\u2013425","journal-title":"Cell Metab"},{"key":"3458_CR4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12095","volume":"78","author":"YC Woo","year":"2013","unstructured":"Woo YC, Xu A, Wang Y, Lam KS (2013) Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 78:489\u2013496","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3458_CR5","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","volume":"55","author":"W Wente","year":"2006","unstructured":"Wente W, Efanov AM, Brenner M et al (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways. Diabetes 55:2470\u20132478","journal-title":"Diabetes"},{"key":"3458_CR6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","volume":"148","author":"A Kharitonenkov","year":"2007","unstructured":"Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774\u2013781","journal-title":"Endocrinology"},{"key":"3458_CR7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang X, Yeung DC, Karpisek M et al (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246\u20131253","journal-title":"Diabetes"},{"key":"3458_CR8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","volume":"53","author":"H Li","year":"2010","unstructured":"Li H, Fang Q, Gao F et al (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53:934\u2013940","journal-title":"J Hepatol"},{"key":"3458_CR9","doi-asserted-by":"crossref","first-page":"e15534","DOI":"10.1371\/journal.pone.0015534","volume":"5","author":"Z Lin","year":"2010","unstructured":"Lin Z, Wu Z, Yin X et al (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5:e15534","journal-title":"PLoS One"},{"key":"3458_CR10","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2337\/dc11-0294","volume":"34","author":"C Chen","year":"2011","unstructured":"Chen C, Cheung BM, Tso AW et al (2011) High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34:2113\u20132115","journal-title":"Diabetes Care"},{"key":"3458_CR11","first-page":"113ra126","volume":"3","author":"AL Wu","year":"2011","unstructured":"Wu AL, Kolumam G, Stawicki S et al (2011) Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 3:113ra126","journal-title":"Sci Transl Med"},{"key":"3458_CR12","doi-asserted-by":"crossref","first-page":"162ra153","DOI":"10.1126\/scitranslmed.3004690","volume":"4","author":"IN Foltz","year":"2012","unstructured":"Foltz IN, Hu S, King C et al (2012) Treating diabetes and obesity with an FGF21-mimetic antibody activating the \u03b2Klotho\/FGFR1c receptor complex. Sci Transl Med 4:162ra153","journal-title":"Sci Transl Med"},{"key":"3458_CR13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2337\/db11-0838","volume":"61","author":"J Mu","year":"2012","unstructured":"Mu J, Pinkstaff J, Li Z et al (2012) FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61:505\u2013512","journal-title":"Diabetes"},{"key":"3458_CR14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333\u2013340","journal-title":"Cell Metab"},{"key":"3458_CR15","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/ncomms3019","volume":"4","author":"A Planavila","year":"2013","unstructured":"Planavila A, Redondo I, Hondares E et al (2013) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4:2019","journal-title":"Nat Commun"},{"key":"3458_CR16","doi-asserted-by":"crossref","first-page":"H1446","DOI":"10.1152\/ajpheart.00362.2012","volume":"303","author":"SQ Liu","year":"2012","unstructured":"Liu SQ, Tefft BJ, Roberts DT et al (2012) Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. Am J Physiol Heart Circ Physiol 303:H1446\u2013H1458","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3458_CR17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2840-3-9","volume":"3","author":"FIELD Study Investigators","year":"2004","unstructured":"FIELD Study Investigators (2004) The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. Cardiovasc Diabetol 3:9","journal-title":"Cardiovasc Diabetol"},{"key":"3458_CR18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849\u20131861","journal-title":"Lancet"},{"key":"3458_CR19","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","volume":"373","author":"K Rajamani","year":"2009","unstructured":"Rajamani K, Colman PG, Li LP et al (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373:1780\u20131788","journal-title":"Lancet"},{"key":"3458_CR20","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","volume":"370","author":"AC Keech","year":"2007","unstructured":"Keech AC, Mitchell P, Summanen PA et al (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687\u20131697","journal-title":"Lancet"},{"key":"3458_CR21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurheartj\/ehp377","volume":"31","author":"DC Burgess","year":"2010","unstructured":"Burgess DC, Hunt D, Li L et al (2010) Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 31:92\u201399","journal-title":"Eur Heart J"},{"key":"3458_CR22","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1210\/jc.2012-2267","volume":"97","author":"KL Ong","year":"2012","unstructured":"Ong KL, Rye KA, O\u2019Connell R et al (2012) Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 97:4701\u20134708","journal-title":"J Clin Endocrinol Metab"},{"key":"3458_CR23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2840-4-13","volume":"4","author":"R Scott","year":"2005","unstructured":"Scott R, Best J, Forder P et al (2005) Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 4:13","journal-title":"Cardiovasc Diabetol"},{"key":"3458_CR24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/ATVBAHA.108.178228","volume":"29","author":"MR Taskinen","year":"2009","unstructured":"Taskinen MR, Sullivan DR, Ehnholm C et al (2009) Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 29:950\u2013955","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3458_CR25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"3458_CR26","first-page":"1","volume":"248","author":"D Pasta","year":"2009","unstructured":"Pasta D (2009) Learning when to be discrete: continuous vs. categorical predictors. SAS Glob Forum Pap 248:1\u201310","journal-title":"SAS Glob Forum Pap"},{"key":"3458_CR27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1536867X1001000303","volume":"10","author":"RB Newson","year":"2011","unstructured":"Newson RB (2011) Comparing the predictive powers of survival models using Harrell\u2019s C or Somers\u2019 D. Stata J 10:339\u2013358","journal-title":"Stata J"},{"key":"3458_CR28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, D\u2019Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157\u2013172","journal-title":"Stat Med"},{"key":"3458_CR29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","volume":"30","author":"MJ Pencina","year":"2011","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11\u201321","journal-title":"Stat Med"},{"key":"3458_CR30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1009612305785","volume":"4","author":"S May","year":"1998","unstructured":"May S, Hosmer DW (1998) A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 4:109\u2013120","journal-title":"Lifetime Data Anal"},{"key":"3458_CR31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1475-2840-12-124","volume":"12","author":"Y Shen","year":"2013","unstructured":"Shen Y, Ma X, Zhou J et al (2013) Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 12:124","journal-title":"Cardiovasc Diabetol"},{"key":"3458_CR32","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","volume":"33","author":"WS Chow","year":"2013","unstructured":"Chow WS, Xu A, Woo YC et al (2013) Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 33:2454\u20132459","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3458_CR33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diabres.2013.04.010","volume":"101","author":"M Lenart-Lipi\u0144ska","year":"2013","unstructured":"Lenart-Lipi\u0144ska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J (2013) Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract 101:194\u2013200","journal-title":"Diabetes Res Clin Pract"},{"key":"3458_CR34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cen.12134","volume":"80","author":"Y Lee","year":"2014","unstructured":"Lee Y, Lim S, Hong ES, Kim JH et al (2014) Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf) 80:57\u201364","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2 Suppl","key":"3458_CR35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/2047487312448988","volume":"19","author":"G Backer de","year":"2012","unstructured":"de Backer G, Graham I, Cooney MT (2012) Do novel biomarkers add to existing scores of total cardiovascular risk? Eur J Prev Cardiol 19(2 Suppl):14\u201317","journal-title":"Eur J Prev Cardiol"},{"key":"3458_CR36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.atherosclerosis.2013.03.017","volume":"228","author":"N Ahluwalia","year":"2013","unstructured":"Ahluwalia N, Blacher J, Szabo de Edelenyi F et al (2013) Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis 228:478\u2013484","journal-title":"Atherosclerosis"},{"key":"3458_CR37","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/j.1600-6143.2012.04147.x","volume":"12","author":"S Kosola","year":"2012","unstructured":"Kosola S, Lampela H, Gylling H et al (2012) Cholesterol metabolism altered and FGF21 levels high after pediatric liver transplantation despite normal serum lipids. Am J Transplant 12:2815\u20132824","journal-title":"Am J Transplant"},{"key":"3458_CR38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","volume":"62","author":"KM Habegger","year":"2013","unstructured":"Habegger KM, Stemmer K, Cheng C et al (2013) Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62:1453\u20131463","journal-title":"Diabetes"},{"key":"3458_CR39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/dna.2013.2290","volume":"33","author":"XL Lin","year":"2014","unstructured":"Lin XL, He XL, Zeng JF et al (2014) FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1\/2-PPAR\u03b3-LXR\u03b1 pathway in THP1 macrophage-derived foam cells. DNA Cell Biol 33:514\u2013521","journal-title":"DNA Cell Biol"},{"key":"3458_CR40","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cyto.2013.02.019","volume":"62","author":"H Stepan","year":"2013","unstructured":"Stepan H, Kley K, Hindricks J et al (2013) Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia. Cytokine 62:322\u2013326","journal-title":"Cytokine"},{"key":"3458_CR41","doi-asserted-by":"crossref","first-page":"e18398","DOI":"10.1371\/journal.pone.0018398","volume":"6","author":"Z Lin","year":"2011","unstructured":"Lin Z, Zhou Z, Liu Y et al (2011) Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 6:e18398","journal-title":"PLoS One"},{"key":"3458_CR42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/cen.12380","volume":"80","author":"J Hindricks","year":"2014","unstructured":"Hindricks J, Ebert T, Bachmann A et al (2014) Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf) 80:918\u2013924","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3458_CR43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-12-0367","volume":"216","author":"S Kralisch","year":"2013","unstructured":"Kralisch S, T\u00f6njes A, Krause K et al (2013) Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J Endocrinol 216:135\u2013143","journal-title":"J Endocrinol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-014-3458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-014-3458-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-014-3458-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T20:20:45Z","timestamp":1566073245000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-014-3458-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,26]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["3458"],"URL":"https:\/\/doi.org\/10.1007\/s00125-014-3458-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,26]]}}}